• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

    61.80 -0.93 (-1.48%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about BridgeBio Pharma, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
    The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
    Via MarketMinute
    Topics Artificial Intelligence Intellectual Property
    Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
    The company easily beat third-quarter expectations and issued guidance that widely topped forecasts. 
    Via Investor's Business Daily
    BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss
    BridgeBio Pharma's Q3 2025 earnings show a major revenue beat driven by Attruby sales, but a widened quarterly loss led to a negative market reaction. 
    Via Chartmill
    Earnings Scheduled For October 29, 2025
     
    Via Benzinga
    Earnings Outlook For BridgeBio Pharma
     
    Via Benzinga
    Earnings Scheduled For August 5, 2025
     
    Via Benzinga
    Earnings Scheduled For April 29, 2025
     
    Via Benzinga
    A Look Ahead: BridgeBio Pharma's Earnings Forecast
     
    Via Benzinga
    BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder
    BridgeBio's Encaleret met its Phase 3 endpoint in ADH1, with 76% achieving calcium targets, supporting plans for FDA and EMA submissions in 2026. 
    Via Benzinga
    BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results
    76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment. 
    Via Stocktwits
    BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High
    A second positive "domino" fell for BridgeBio on Wednesday after the company reported promising results in a genetic disease. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Tuesday's After-Market Session
     
    Via Benzinga
    Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
     
    Via Benzinga
    BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial
    BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026. 
    Via Stocktwits
    BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition
    BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study. 
    Via Benzinga
    BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival
    The company ran an exploratory analysis of its drug, Attruby, in patients with cardiomyopathy due to TTR amyloidosis. 
    Via Investor's Business Daily
    BridgeBio Pharma Inc (NASDAQ:BBIO) Shows Strong Technical Setup for Potential Breakout
    BridgeBio Pharma (BBIO) shows strong technicals with a perfect 10 rating. Currently in a consolidation pattern, it may be poised for a breakout above resistance, offering a potential entry for... 
    Via Chartmill
    10 Health Care Stocks Whale Activity In Today's Session
     
    Via Benzinga
    BRIDGEBIO PHARMA INC (NASDAQ:BBIO) Shows Strong Technical Breakout Potential with High Momentum and Consolidation Setup
    BridgeBio Pharma (BBIO) shows strong breakout potential with a perfect Technical Rating of 10 and Setup Rating of 9, signaling robust momentum and consolidation. Ideal for traders eyeing... 
    Via Chartmill
    BridgeBio Pharma Inc (NASDAQ:BBIO) Shares Drop 11% After Q2 2025 Earnings Miss Despite Revenue Beat
    BridgeBio Pharma reports mixed Q2 2025 results with revenue beating estimates but EPS missing, causing an 11% stock drop. Strong prescription growth contrasts with profitability concerns. 
    Via Chartmill
    Topics Earnings
    10 Health Care Stocks Whale Activity In Today's Session
     
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
     
    Via Benzinga
    Is Pfizer Stock a Yield Trap?
    Via The Motley Fool
    Topics Intellectual Property
    Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
    Via The Motley Fool
    Topics Intellectual Property Retirement
    The Smart Money Is Buying These 10 Stocks
     
    Via Benzinga
    Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
    Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility. 
    Via Benzinga
    Topics World Trade
    BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
    The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market. 
    Via Investor's Business Daily
    Competitive Analysis In The ATTR-CM Field
    Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
    Via Talk Markets
    Topics Stocks / Equities
    Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
    BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it. 
    Via Benzinga
    Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
    Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.